Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remogliflozin etabonate - Avolynt/Kissei-Pharmaceutical

Next Previous
X
Search
Drug Profile

Remogliflozin etabonate - Avolynt/Kissei-Pharmaceutical

Alternative Names: 189075; BHV-091009; GSK-189075; KGT-1681; Remo; Remogliflozin; Remozen; Zucator

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Avolynt; BHV Pharma; GlaxoSmithKline; Glenmark Pharmaceuticals Ltd; Kissei Pharmaceutical
  • Class Antihyperglycaemics; Benzene derivatives; Carbonates; Glucosides; Hepatoprotectants; Pyrans; Pyrazoles
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis
  • Discontinued Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 11 Jul 2019 Glenmark and Torrent signs sub-licensing agreement to co-market Remogliflozin etabonate in India
  • 03 May 2019 Discontinued - Phase-I for Obesity in USA (PO) (Avolynt pipeline, May 2019)
  • 03 May 2019 Discontinued - Phase-I for Type 1 diabetes mellitus in USA (PO) (Avolynt pipeline, May 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top